Myotonic Dystrophy Type 1 Dm1 clinical trials

Explore recruiting myotonic dystrophy type 1 dm1 clinical trials.

Recruiting myotonic dystrophy type 1 dm1 studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myotonic Dystrophy Type 1 Dm1 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I

Netherlands, France, Italy, Spain, Germany, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

EVALUATION OF THE EFFICACY AND SAFETY OF METFORMIN IN THE MYOTONIC DYSTROPHY TYPE I (STEINERT’S DISEASE). PHASE III PROSPECTIVE, MULTICENTRE, RANDOMISED, DOUBLE-BLIND CONTROLLED STUDY.

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of Intravenous Administration of ATX-01 In Male and Female Participants aged 18 to 64 with Classic Myotonic Dystrophy Type 1 (DM1)

Italy, France, Spain, Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2, Randomized, Double-blind, Placebo‑controlled Single- and Multiple‑dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX‑670 in Adult Subjects with Myotonic Dystrophy Type 1

Netherlands, Spain, Belgium, France, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Myotonic Dystrophy Type 1 Dm1 trials by city

Myotonic Dystrophy Type 1 Dm1 clinical trials

Recruiting myotonic dystrophy type 1 dm1 studies right now

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)

Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)

Study of ATX-01 in Participants With DM1

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Herombopag Treated T-DM1 Induced Platelet Reduction

A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

Also recruiting in Europe

An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects with Myotonic Dystrophy Type I

EVALUATION OF THE EFFICACY AND SAFETY OF METFORMIN IN THE MYOTONIC DYSTROPHY TYPE I (STEINERT’S DISEASE). PHASE III PROSPECTIVE, MULTICENTRE, RANDOMISED, DOUBLE-BLIND CONTROLLED STUDY.

A Phase 1/2, Randomized, Double-blind, Placebo‑controlled Single- and Multiple‑dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX‑670 in Adult Subjects with Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1 Dm1 trials by city

Other conditions